% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Shahid:285810,
author = {Shahid, Hadiqa and Sohail, Tehreem and Noor, Aneeqa and
Zafar, Saima},
title = {{A} {S}ystematic {R}eview of the {A}pplications of {C}arbon
{D}ots for the {T}reatment of {D}iabetes},
journal = {Journal of drug delivery science and technology},
volume = {114},
issn = {1157-1489},
address = {Paris},
publisher = {Ed. de Santé},
reportid = {DZNE-2026-00346},
pages = {107497},
year = {2025},
abstract = {Diabetes mellitus is a chronic disease which is defined by
persistent hyperglycemia and long-term complications which
include neuropathy, nephropathy, and impaired wound healing.
Conventional therapies face limitations like side effects,
poor drug bioavailability, and invasive monitoring methods.
This systematic review examines the recent studies that have
been done for the use and administration of carbon dots
(CDs), that are small biocompatible nanomaterials for
diabetes treatment and diagnosis. Drawing from in vitro and
in vivo studies, we highlight the nitrogen-doped CDs for
α-glucosidase inhibition, plant-derived CDs for glucose
regulation, sulfur and boron/sulfur-doped CDs for
non-enzymatic glucose sensing, nitrogen-doped and
metformin-derived CDs for insulin delivery, chiral CDs for
amyloid aggregation control, Arg CDs and pristine C60
fullerenes for antioxidant and anti-inflammatory activity,
Zingiberis-based CDs for hepatoprotection, Zn/C-dots and
VEGF-loaded nanodots for wound repair and nerve regeneration
and glucose-derived CDs for blood-brain barrier penetration.
These functionalized systems use heteroatom doping and
surface engineering to combine therapeutic and diagnostic
potential, protect β-cells, improve medication absorption,
and allow non-invasive glucose monitoring. Notably, several
nanodots originally developed for unrelated biomedical
purposes have also shown properties beneficial for diabetes
management, showing opportunities for repurposing, though
further validation in diabetic models is required. While CDs
show promise as an integrated platform for managing diabetes
and its complications, critical challenges remain in
achieving scalable, reproducible synthesis, ensuring
long-term safety, and optimizing targeted biodistribution.
Future work should prioritize standardized production,
mechanistic studies and extended preclinical and clinical
evaluation to facilitate translation into effective,
patient-friendly nanotherapeutics.},
subtyp = {Review Article},
cin = {AG Zerr},
ddc = {610},
cid = {I:(DE-2719)1440011-1},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
doi = {10.1016/j.jddst.2025.107497},
url = {https://pub.dzne.de/record/285810},
}